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Inflammation may also contribute to the PPE in EGFRi leading
to postinflammatory hyperpigmentation, particularly given the
high frequency of face and neck involvement in all patients.
However, in our series, all patients were affected with this
new EDP-like eruption in areas not typically affected by PPE
(e.g. tongue and axillae). No patients were receiving medica-
tions associated with drug-induced EDP, such as omeprazole
or ethambutol.5,6 Only one patient was receiving doxycycline
at the time of the eruption, and this drug is less associated
with pigmentation than minocycline.
One limitation of our study is that while PPEs are com-
mon early on during treatment with EGFRi, only one of our
patients had a previous PPE documented. This may be due
to the EDP-like reaction presenting later in treatment relative
to PPE. PPEs are quite common in patients on EGFRi, so it
is also possible that these patients are not representative.
Additionally, the patients in this cohort may have had a pre-
viously mild or transient PPE that they did not seek prior
medical management for, and some had been on prophylac-
tic antibiotics. Another limitation is that only two patients
had skin biopsies performed. Lastly, causation cannot be pro-
ven with a case series, but we hope this opens the door for
future investigation.
Given the visible impact and long-lasting nature of the skin
discoloration in our patients, which led to significant morbid-
ity and distress, and lack of successful topical management,
we hope that this novel observation will lead to increased
recognition, further studies to understand the pathogenesis of
this association, and exploration of more effective manage-
ment strategies which will be critical to enhancing patients’
quality of life.
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Active vs. standard sun protection in patients
with melanoma stage I or II: a randomized
controlled feasibility trial assessing compliance
with sun protection and quality of life
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The incidence of melanoma is steadily increasing in Western
countries; a key factor is ultraviolet exposure. Sun protection is
essential, particularly in patients with diagnosed melanoma.
However, data on the psychological implications of sunscreen
protection in patients with melanoma are lacking. This project
was designed as a randomized controlled feasibility trial to
explore the feasibility of the diary method and tube count to
assess patient compliance in a monocentric trial, and to observe
any recognizable trends regarding anxiety and quality of life
(QoL) between the intervention and control group. The end-
points were compliance with sun protection assessed by diary
documentation and tube weights, and anxiety level assessed with
a questionnaire set, including the Hospital Anxiety and Depres-
sion Scale – Depression only (HADS-D; German version), Derma-
tology Life Quality Index (DLQI) and the five-level EQ5D
(EQ5D-5L). Feasibility was the aim of this trial, no formal a pri-
ori sample size calculation was conducted and a sample size of
about 30 patients was targeted to get robust parameter esti-
mates.1 Eligible patients had to meet the following criteria: histo-
logically confirmed, completely resected nonocular, nonmucosal
melanoma stage I or II; age 18–75 years; participation in the fol-
low-up programme in the first and second year after surgery;
and informed consent provided. The trial was approved by the
local ethics committee (reference no.: 17-757-101) and regis-
tered with the World Health Organization clinical trials database
(reference no.: DRKS00014331). It was conducted between April
and November 2018 at the Department of Dermatology of the
University Hospital Regensburg (UKR). All participating patients
received standard-of-care information from the national German
guidelines on the use of individual sun protection.2 In addition,
patients in the intervention group were provided with 300 g
sunscreen with a sun protection factor of 50+ (six tubes) for the
follow-up period (3 months). Participants’ sunscreen use was
assessed by means of a pseudonymized, calendar-like patient
diary enabling the differentiation between multiple uses of
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sunscreen per day for an observation period of 12 weeks. At
study end, the diaries and tubes of sunscreen were returned. The
remaining sunscreen was weighed. The questionnaire set was
completed before and at follow-up. Continuous data are pre-
sented as median [interquartile range (IQR)], and between-group
differences were calculated using the Wilcoxon Mann–Whitney
test. Categorical variables are presented as absolute values and rel-
ative frequencies and were compared using the 2 test of indepen-
dence or the Mantel–Haenszel test. QoL was analysed using a
repeated-measures ANOVA and the results are presented as esti-
mated marginal means with corresponding 95% confidence
intervals. A P-value < 005 was considered statistically significant.
All analyses were conducted using SPSS version 250.02 for Mac
(IBM, Armonk, NY, USA) and SAS 94 (SAS Institute, Cary, NC,
USA), which was also used for proc plan randomization (Centre
for Clinical Studies, UKR). Thirty-two of 51 eligible patients
consented to participate. Median age was 52 years (IQR 38–61).
Seventeen (53%) patients were allocated to the intervention
group and 15 (47%) to the control group. Thirty (94%) patient
diaries were returned and analysed. Fifteen of 17 sunscreen
rations were returned and weighed. Regarding the endpoints, no
significant differences were found between the intervention and
control group. Mean HADS subscales and the EuroQol visual ana-
logue scale scores and DLQI scores were comparable with those
of the reference population.3,4
Our patients used a median amount of 23 g (IQR 16–29)
of sunscreen, which results in a median application of
12 mg cm–2 as calculated for an average body surface
(Table 1). This is below the 2 mg cm–2 sunscreen protection
recommended by the national German guidelines.2,5–7 Previously
published data on the quantity of sunscreen use found thick-
nesses far below 1 mg cm–28 Yet, we believe the use of just a
Table 1 Sun protection frequency and quality of life scores
Intervention group (n = 15) Control group (n = 15) P-value
Median (IQR) no. of days with at least
one application
44 (24–63) 34 (17–66) 0486
Median (IQR) total no. of applications 49 (32–73) 42 (21–66) 0520
Patients with no applications, n (%) 1 (7) 1 (7) 100
Median (IQR) total amount of sunscreen
used in grams (intervention only)
96 (49–162) a,b –
Median (IQR) g per application of
sunscreen (intervention only)
23 (16–29) a,b –
Calculation sunscreen application on
body surface/cm2 (mg)c
12
QoL scores Intervention group (n = 15)b Control group (n = 15)b P-valueb
HADS-Ad Baseline 499 (317–680) 600 (404–796) 0442
Follow-up 485 (345–625) 445 (294–596) 0695
Difference 013 (–105 to 132) 155 (027–283) –
P-value 0815 0019
HADS-Dd Baseline 308 (151–464) 350 (182–519) 0708
Follow-up 314 (188–440) 285 (149–421) 0754
Difference –006 (–135 to 123) 065 (–074 to 204) –
P-value 0924 0347
DLQId Baseline 571 (257–884) 585 (247–923) 0949
Follow-up 409 (231–588) 335 (143–528) 0568
Difference 161 (–095 to 418) 250 (–027 to 527) –
P-value 0208 0075
EQ5D index valued Baseline 092 (086–099) 089 (082–096) 0496
Follow-up 093 (090–096) 095 (092–098) 0295
Difference –0003 (–007 to 006) –006 (–013–001) –
P-value 0932 0087
EQ5D VASd Baseline 785 (703–867) 738 (649–826) 0423
Follow-up 823 (758–888) 843 (772–913) 0676
Difference –37 (–115 to 41) –105 (–189 to –21) –
P-value 0335 0016
aThe control group was not actively supplied with sunscreen. bResults are presented as estimated marginal means with corresponding 95%
confidence intervals adjusted for sex. A P-value < 005 was considered statistically significant. cBased on Microzensus5 data for model surface
of 9% (equal to the surface of an arm according to the Mosteller formula:6 body surface in [m2 =
p
height \ in\ cm 9 weight\ in\ kg/
3600] and the Wallace ‘rule of nines’, which is a tool used in clinical and emergency medicine to estimate the total body surface affected by
a burn.7 dEach quality of life measurement [Hospital Anxiety and Depression Scale (HADS), Dermatology Life Quality Index (DLQI) and
EQ5D)] was analysed using a repeated-measures ANOVA, with time as an within-subject factor and the type of treatment as a between-subject
factor. HADS-A, Hospital Anxiety and Depression Scale – Anxiety; HADS-D, Hospital Anxiety and Depression Scale – Depression.
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little sunscreen is preferable to no use at all. Overall, the follow-
ing valuable lessons have been learned for the design and sample
size calculation of subsequent trials. Diary-based documentation
and tube count are feasible in the context of a randomized clini-
cal trial to assess compliance with sunscreen protection. To
enhance the correct use of sunscreen, an updated version of the
diary should contain pictograms to mark the body surface to be
covered with cream. Reminding participants of their scheduled
second appointment improved their compliance with the study
regime. The questionnaires were acceptable to patients, with no
missing values or forms, and should be used in subsequent
trials.
These lessons will be implemented in future studies to
improve our understanding of the psychological causes and
effects of sunscreen protection.
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Comparison of registered and published
outcomes in randomized trials in dermatology
journals: a cross-sectional analysis
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DEAR EDITOR, A potential source of bias in randomized con-
trolled trials (RCTs) is selective outcome reporting bias, where
outcomes for reporting are chosen based on the significance
of their results.1 Significance can arise by chance when multi-
ple tests are performed (‘data dredging’). To avoid this prob-
lem, a main outcome (a ‘primary outcome’) should be
prespecified prior to data collection in a time-stamped, pub-
licly available trial registry. Prospective registration has been a
prerequisite for publication among International Committee of
Medical Journal Editors member journals since 2005. How-
ever, even when trials are registered prospectively, selective
outcome bias reporting can occur if the primary outcome
reported in the manuscript does not match the prespecified
primary outcome in the trial registry.2
We assessed primary outcome discrepancies in RCTs pub-
lished in the top 10 dermatology journals, based on 2017 Clari-
vate impact factors. Tables of contents for each journal were
reviewed by two authors (L.S., A.L.) for full reports of RCTs pub-
lished between January 2017 and December 2017. Phase 0 or I
studies and secondary or pooled analyses were excluded. Full
texts were reviewed by at least two authors (L.S., A.L., A.H.),
and disagreements were resolved by an additional author (J.T.).
Manuscripts were assessed for trial registration numbers.
These were inputted into the World Health Organization
International Clinical Trials Registry Platform (ICTRP) to deter-
mine prospective trial registration status, which it defined as a
‘date of registration prior to the date of first enrolment’. If a
trial registration number could not be identified, the trial
intervention was searched for on ICTRP.
We compared the prospectively registered primary outcome
on the trial registry against the reported primary outcome in
the manuscript. As time-stamped modifications to trial reg-
istries can be made after study initiation, we used the primary
outcome that was registered before study initiation. A major
discrepancy in primary outcome was defined using a modified
classification2 of Chan et al.:1 (i) a registered primary outcome
was reported as a secondary outcome, (ii) a registered primary
outcome was omitted, (iii) an unregistered outcome was
introduced as a primary outcome, (iv) a registered secondary
outcome was reported as the primary outcome and/or (v) the
time of primary outcome assessment differed (excluding
extension studies). ‘Imprecise reporting’ referred to discrepan-
cies not meeting this definition.
The study population included 65 trials from six journals.
Four of the journals required prospective trial registration dur-
ing the study period (JAMA Dermatology, Journal of the American
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